Innovent Biologics announced a global strategic licensing and collaboration agreement with Pfizer focused on the research and development of 12 early-stage and de novo oncology programs, creating one of the largest oncology partnerships announced this year. The deal combines Innovent’s oncology discovery and early clinical development capabilities with Pfizer’s global development, regulatory, and commercialization expertise.
The collaboration covers a portfolio of 12 programs, including eight Innovent-originated early-stage assets and four Pfizer-proposed discovery programs. The portfolio spans antibody-drug conjugates (ADCs) featuring novel payload technologies and multi-specific antibodies designed with differentiated immune-engaging mechanisms.
Under the agreement, Innovent will lead development of the programs through Phase 1 clinical trials, leveraging its proprietary discovery platform and early-stage clinical development infrastructure. Following Phase 1, Pfizer will assume leadership of global development activities.
The partnership includes three distinct development and commercialization structures:
- Four programs will be co-developed globally, with both companies sharing development costs. The companies will co-commercialize these assets in the United States and Europe and share profits, while Innovent will retain rights in Greater China.
- Four programs will be licensed exclusively to Pfizer outside Greater China, with Pfizer assuming the majority of development expenses.
- Four programs will receive exclusive global licenses from Innovent to Pfizer, with Pfizer responsible for all global development costs.
Under the financial terms of the agreement, Innovent will receive a $650 million upfront payment and could earn up to $9.85 billion in development, regulatory, and commercial milestone payments. The transaction therefore carries a potential total value of up to $10.5 billion. Innovent is also eligible to receive royalties reaching double-digit percentages on approved licensed products. For co-developed and co-commercialized programs, the companies will share profits generated in the United States and Europe.
The transaction remains subject to customary regulatory approvals and closing conditions.
Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) at Innovent, said the agreement combines the strengths of both organizations to accelerate the advancement of innovative cancer medicines globally while expanding Innovent’s presence in major international markets.
Pfizer Chief Oncology Officer Jeff Legos said the collaboration brings together complementary innovation capabilities and provides an opportunity to strengthen the company’s oncology pipeline while accelerating the development of transformative cancer treatments for patients worldwide.
Founded in 2011, Innovent has developed a portfolio of 18 commercialized products and maintains a pipeline that includes five Phase III or pivotal-stage assets and 14 additional molecules in early clinical development. The company has established partnerships with more than 30 global healthcare organizations.
KEY QUOTES:
“This agreement brings together best-in-industry expertise of Pfizer and Innovent to advance novel cancer medicines to patients at a global scale. By leveraging both companies’ complementary resources, we can develop our early-stage oncology pipeline with greater speed and impact to help bring innovative therapies to patients more efficiently worldwide. Furthermore, co-developing and co-commercializing key projects in the U.S. and Europe expands Innovent’s global reach. At Innovent, we are laying the foundation for a truly global oncology platform that can deliver meaningful and lasting benefits for patients around the world.”
Hui Zhou, Chief R&D Officer (Oncology Pipeline), Innovent Biologics
“At Pfizer, everything we do starts with patients and the urgency to change what’s possible for people living with cancer. This collaboration brings together two highly complementary engines of innovation with a shared ambition to move faster, go further and deliver truly transformative medicines to patients who are waiting. By combining Innovent’s discovery and early clinical development with Pfizer’s global research and development and commercialization capabilities, we have an opportunity not only to strengthen our pipeline, but to accelerate the delivery of breakthroughs that can redefine standards of care and make a meaningful difference in patients’ lives.”
Jeff Legos, Chief Oncology Officer, Pfizer
